Seeking Alpha

Stifel Nicolaus initiates Sarepta Therapeutics with a Buy

  • Sarepta Therapeutics (SRPT +1.2%) moves up today after Stifel Nicolaus initiated the shares late yesterday with a Buy and a $51 price target.
  • Stifel says the company represents an attractive investment biotechnology opportunity in the rare orphan disease space.
  • Its thesis is predicated on the clinical and commercial success of Eteplirsen, its lead pipeline asset, which has already demonstrated compelling safety and tolerability in a Phase 2b clinical study.
  • In addition, SRPT's broad platform technology gives them a leg-up for potentially discovering additional clinical candidates for genetically inherited and difficult to treat infectious diseases.
Comments (1)
  • dbj501
    , contributor
    Comments (2) | Send Message
    45 years in finance industry. Read everything ! Long term and not a trader(not good at it). Some really big hits in my lifetime..
    5 really. Few trades a year but large ones. Usually scale in.
    7 Sep 2013, 03:42 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: